Double Blind, Placebo Controlled Evaluation of a Novel Skin Lightening Agent.
Melasma remains a troubling problem for physicans and patients alike. It is a chronic irregular, symmetric hyperpigmentation seen most often in women. In this study, a unique combination of ingredients with non-irritating properties was tested for treatment of melasma. In a double blind, placebo controlled, split face trial, 17 patients with melasma were treated on one half of the face, left or right, while the other received placebo control. All patients used sunscreen on both sides. Measurement with a colorimeter (Mexameter) was taken at baseline and after 8 weeks of daily use. The active side showed an objective decrease in hyperpigmentation of 14.60% while the control side showed a decrease of 9.82%. We conclude the product provides a non-irritating effective therapy for melasma. <p><em>J Drugs Dermatol. 2018;17(1):113-115.</em></p>.